Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given a consensus rating of “Moderate Buy” by the fourteen research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $52.7692.

CLDX has been the subject of a number of analyst reports. UBS Group increased their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Guggenheim lifted their price target on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Barclays upped their price target on Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Cantor Fitzgerald decreased their price objective on Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Wells Fargo & Company lowered their price objective on Celldex Therapeutics from $54.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Wilmington Savings Fund Society FSB purchased a new stake in shares of Celldex Therapeutics during the third quarter worth about $42,000. Russell Investments Group Ltd. raised its position in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Celldex Therapeutics in the 3rd quarter worth approximately $63,000. Kestra Advisory Services LLC acquired a new stake in Celldex Therapeutics in the 4th quarter worth approximately $98,000. Finally, Advisory Services Network LLC purchased a new stake in Celldex Therapeutics during the 3rd quarter worth approximately $139,000.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock opened at $35.28 on Friday. Celldex Therapeutics has a one year low of $19.72 and a one year high of $40.30. The company has a market capitalization of $2.77 billion, a PE ratio of -8.28 and a beta of 0.90. The company has a 50-day simple moving average of $33.64 and a two-hundred day simple moving average of $30.68.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.80 million. On average, equities analysts predict that Celldex Therapeutics will post -4.36 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.